Study Summary
This trialtests a new imaging tech to detect small pancreatic cancer in people with the disease. It may help accurately identify cancer in resected tissue.
- Pancreatic Cancer
- Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Up to 3 years
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Diagnostic (resection, OCT)
1 of 1
Experimental Treatment
75 Total Participants · 1 Treatment Group
Primary Treatment: Optical Coherence Tomography · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many participants is the clinical trial currently accommodating?
"Affirmative. Clinicaltrials.gov presents evidence that this experiment is currently attempting to recruit participants, with the first post being on March 26th 2019 and the latest edit occurring on November 22nd 2022. In total, 75 individuals are needed from one medical facility." - Anonymous Online Contributor
Is this research initiative currently seeking participants?
"Clinicaltrials.gov notes that this study is accepting participants, having been first published on March 26th 2019 and most recently revised on November 22nd 2022." - Anonymous Online Contributor